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Introduction 1
Liposarcoma (LPS), a neoplasm arising within adipose tissue which is thought to 2 originate from mesenchymal stem cells, 1-3 is a type of soft tissue sarcoma and is associated 3 with poor patient outcomes. [4] [5] [6] LPS is classified into three histologic subtypes: well-4 differentiated (WD)/ dedifferentiated (DD), which is the most prevalent subtype, pleomorphic, 5
and myxoid/round cell. The extent of differentiation, as reflected by histologic grade, remains 6 the most important determinant of patient outcome. The main treatment options for patients 7 with LPS are surgery and radiation, while chemotherapy typically has little effect on the overall 8 prognosis for patients with locally advanced or metastatic disease. 7,8 9 The establishment of a clinically relevant disease model is vital for studying the 10 molecular mechanisms underlying LPS malignant transformation and evaluating emerging 11 targeted therapies. Certain characteristic mutations of LPS have been identified, such as 12 chromosome 12q amplification in WD/DD LPS and a chromosomal translocation in myxoid 13 LPS; 9 however, our knowledge of the cell-of-origin and major pathway alterations associated 14 with LPS is still limited. In this study, we develop a direct LPS xenograft method by implanting 15 and serially passaging freshly resected LPS samples from patients into immune deficient mice. 16
We demonstrate that these xenograft models not only recapitulate the patient tumors but carry a 17 unique gene expression signature and can be used for testing targeted treatment. 18
Materials and Methods 19
Collection of tumor samples. Patients with a suspected LPS who underwent surgery at UCLA 20 were enrolled on a UCLA Institutional Review Board approved tissue procurement protocol and 21 gave written informed consent. Each surgically resected tumor was sliced into sections with a 22 sterile razor blade and divided as follows: one portion was immediately frozen and stored at 23 -80°C for genomic and gene expression analyses, a portion of the tumor was fixed in 10% 24 formalin for histology, and the remaining portion was minced into small pieces for xenograft 25 temperature for 10 minutes. After spinning down the cells for 5 minutes at 150 x g, cells were 1 resuspended in complete medium and plated onto 6-well dishes (10 6 cells per well). Cell 2 adhesion was observed 24 hours post plating, and confluent plates were expanded. Cells were 3 maintained in a 37°C incubator with 5% carbon dioxide and monitored for cell adhesion. 4
For inoculation in mice, 70% confluent cells were rinsed with DPBS and treated with 5 0.25% trypsin-EDTA (Invitrogen) until the cells separated from the dish. Complete media was 6 added to quench the trypsin reaction, and the cells were centrifuged at 150 x g for 5 minutes. 7
The supernatant was aspirated and cells were resuspended in DPBS, counted on a 8 hemocytometer using trypan blue exclusion, and adjusted to a concentration of 5x10 6 cells/ml. 9
Mice were anesthetized, shaved, and prepped before 0.5-1.0x10 6 cells were injected 10 subcutaneously with a 28 gauge needle on a 0.5 ml insulin syringe. 11
Histology and immunohistochemistry. The sample was fixed in 10% phosphate buffered 12 formalin overnight and then transferred into 50-70% ethanol. Shortly afterward, the tissue was 13 embedded in paraffin using standard protocols, cut into 4 µm sections, and stained with 14 hematoxylin and eosin (H&E) by the UCLA Translational Pathology Core Laboratory and 15 reviewed by a sarcoma pathologist (S.M.D). Slides were digitally scanned at 400X with the 16 For visualizing lipids, frozen sections were stained in a 0.3% oil red O/isopropyl alcohol 4 solution for 7-10 minutes at room temperature. Excess stain was washed out in 60% isopropyl 5 alcohol, followed by washes in 30% isopropyl alcohol and distilled water. Slides were 6 counterstained with hematoxylin, rinsed with two changes of tap water, and cover slips were 7 mounted with glycerol. Slides were subsequently stored at 4°C. Images were captured on a 8 BX60 (Olympus, Center Valley, PA) microscope with a Microfire camera and PictureFrame 9
software v.2.1 (Optronics, Goleta, CA) and analyzed with Adobe Photoshop CS4. 10 Treatment studies. Tissue from an existing xenograft was dissociated with a 100 µm mesh cell 11 strainer into DPBS. Viable cells were counted with trypan blue exclusion, centrifuged, and 12 resuspended in equal portions of DPBS and Matrigel (BD Biosciences). 5x10 5 cells were 13 injected subcutaneously. Tumors were measured with calipers. When tumors reached 14 approximately 5 mm in diameter, mice were randomly assigned into placebo (vehicle) or 15 treatment groups with minimum of 5 mice per group. Tumor volume was measured twice 16 weekly and calculated as: tumor volume = 0.52*a 2 *b, where a represents the shorter diameter. 17
Rapamycin powder (LC Laboratories) was reconstituted in 100% ethanol to a stock 18 solution of 10 mg/ml and stored at -20°C. Fresh working solution was made each time by 19 diluting the stock solution to 1 mg/ml with vehicle (5.68% Tween-80, 5.68% polyethylene glycol 20 400 in water). Rapamycin (4 mg/kg) or an equal volume of vehicle was administered via 21 intraperitoneal injection daily. Sorafenib pills were weighed, then crushed and stored at -20°C. 22
Powder was dissolved into freshly made vehicle (12.5% ethanol, 12.5% cremaphor in water) to 23 20 mg/ml. Sorafenib (70 mg/kg) or an equal volume of vehicle was administered via oral 24 gavage daily. Mice were treated daily with one of the following combinations: rapamycin vehicle 25 and sorafenib vehicle, rapamycin drug and sorafenib vehicle, sorafenib drug and rapamycin 26 KB Smith et al 8 vehicle, or rapamycin drug and sorafenib drug. Body weight and tumor measurements were 1 collected every three to four days. Tumors were collected and mouse sacrificed if the tumor 2 reached 1.5 cm in either diameter, or if the mouse lost more than 10% of its body weight within 3 one week, whichever occurred first. 4
Triglyceride quantification. Triglycerides were quantified using the Triglyceride Colorimetric 5
Assay Kit following manufacturer's protocol (Cayman Chemicals). Briefly, frozen tumor samples 6 from the treatment study were weighed and homogenized in Standard Diluent Assay Reagent. 7
After applying Triglyceride Enzyme Mixture, the triglyceride standard curve and samples were 8 read at 530 nm using a Benchmark Plus plate reader (Bio-Rad, Philadelphia, PA). Triglyceride 9 levels for each sample were normalized to the weight of tissue homogenized. 10
RNA isolation and gene expression microarray. The patient tumor samples and xenograft 11
passages were prepared and RNA was isolated as described in our previous paper. 10 In gene expression analysis, two-tail t-test was used for comparing expression between 1 groups. For a gene represented by multiple probes, its representative p-value was the lowest p-2 value among the probes. Gene ontology analysis was conducted using pathway databases 3 downloaded from Gene Ontology and Broad Institute Molecular Signature Database. 11,12 4
Fisher's exact test was used to identify the gene ontology or biological pathway significantly 5 enriched by differentially expressed genes between groups (two-tail t-test p<0.05 and fold-6 change>1.5). Cluster 3.0 was used in hierarchical clustering analysis in which the expression 7 profile of each gene was first transformed to z-scores, and then samples were clustered by 8 using average linkage method based on un-centered correlation coefficients as distance metric 9 among samples. 10
Rank-rank hypergeometric overlap (http://systems.crump.ucla.edu/rankrank/) 13 was used 11 to compare gene expression data from our samples versus gene expression of pre-adipocytes 12 collected after 0 and 3 days of induction in differentiation media (GEO accession ID: 13 GSE28628). 14 Inc.), with p<0.05 considered significant. 2
Results 3
Ability to engraft and passage LPS tumor correlates with disease specific survival. To 4 generate clinically relevant LPS models for investigating molecular etiology and evaluating 5 response to targeted therapies, we used a xenotransplantation approach by subcutaneously 6 implanting fresh surgically resected LPS samples into NOD/SCID or NOD/SCID/IL2 -/-(NSG) 7 mice ( Figure 1A ). Over a two year period, we implanted 22 surgically resected tumors 8
[myxoid/round cell (n=5), WD (n=7), and DD (n=10)]. These tumors varied in grade, site of 9 origin, size, and treatment history ( Table 1 ). Of the ten DD samples, eight came from tumors 10 that had both WD and DD components (as indicated by DD* in Table 1 ), but all DD areas were 11 pathologically diagnosed as high grade, and our pathologist (S.M.D.) selected DD areas for 12 processing. Within six months of implantation, seven patient tumors successfully grew in mice 13 (Table 1 , middle and lower rows; 2/5 myxoid/round cell, 0/7 WD, and 5/10 DD), resulting in a 14 32% engraftment rate. All engrafted LPS tumors were high grade, and three of these 15 xenografts, LPSX1, LPSX2 and LPSX3 ( Table 1 , lower rows), could be serially passaged in 16 mice (14% of all tumors, 43% of engrafted tumors). Cells from all three xenografted tumors 17 could be successfully cultured and serially passaged in vitro for 10-17 passages. In contrast, 18 cells isolated directly from patient tumors failed to be serially passaged under the same in vitro 19 culture conditions (data not shown). 20
To determine if there were any clinic-pathologic factors that influenced the ability to 21 establish a xenograft, we evaluated multiple patient characteristics for each sample. Given the 22 small sample size (n=22), this analysis was fairly exploratory to determine possible clinical 23
predictors of a tumor's successful passage and/or engraftment. Univariate analysis of 12 24 clinical variables (see Materials and Methods) revealed that the size of tumor (p=0.084; odds 25 ratio: 0.90; 95% CI: 0.80-1.01) and presence of multifocal disease (p=0.058; odds ratio: 15.35; 1 95% CI: 0.91-257.27) correlated with the ability of an LPS patient sample to be engrafted 2 and/or passaged. On multivariate analysis, tumor size (p=0.052; odds ratio: 0.85; CI: 0.72-3 1.00) and presence of multifocal disease (p=0.026; odds ratio 38.6; CI 1.53-969.13) remained 4 significant, however these results should be interpreted with caution given the low sample size 5 and high variability in the data. Next, we aimed to specifically evaluate the association of 6 engraftment and passagability with disease specific survival (DSS). As expected, the ability to 7 engraft and be passaged significantly correlated with poor DSS on univariate analysis 8 (p<0.0001, Mantel-Cox test). Patients whose samples could be xenografted and serially 9 passaged died of disease within 200 days of tumor removal ( Figure 1B , red line; n=3), in sharp 10 contrast to those patients whose tumors did not grow ( Figure 1B , black line; n=15, p<0.0001, 11
Mantel-Cox test). Patients whose samples engrafted but could not be passaged also had a 12 significantly better survival than those that could be passaged ( Figure 1B, these data suggest that the xenograftability of LPS can be used for studying key molecular and 17 genetic alterations associated with the aggressive phenotype of LPS. 18
Xenografted tumors recapitulate histopathologic and gene expression features of the 19
patient tumors. To ensure that the xenografts recapitulate the patient disease, we compared 20 surgically resected patient tumors with their derivatives, i.e., xenograft tumors that had been 21 passaged in vivo. Representative histologic images from the patient tumor LPSX3 and its 22 resulting xenografts passaged in vivo for 1-9 passages demonstrated that no major 23 morphologic changes occurred during serial passage ( Figure 1C ). We also compared in vitro 24 cultured cells and different tissue dissociation and maintenance methods before transplantation 25 into mice and found no resulting histopathologic differences or proliferation rates, as measured 26 by Ki67 index ( Figure S1 ). These analyses demonstrate that in vivo passaged and culture-1 derived xenografts maintain the histologic features of the patient tumors. 2
We also looked at specific genetic alterations associated with LPS to confirm that the 3 xenograft model accurately reflects the patient disease. Previous work published by our group 10 4 and others 17-21 identified characteristic amplicons on chromosome 12q in most WD and DD LPS 5 tumors. Our comparative genomic hybridization (CGH) array analysis showed that passagable 6 patient tumors indeed carry amplifications in this region ( Figure S2A ). Amplicon-associated 7
genes, e.g. MDM2 and CDK4, showed similar gene expression upregulation in the patient 8 tumors and their corresponding xenografts ( Figure S2B ). These analyses indicate that the 9 xenograft models recapitulate both histopathologic and molecular features of the patient disease 10 and therefore are suitable models for studying LPS. 11
Xenograftability is associated with aggressive proliferation and invasion signatures as 12
well as upregulated PI3K/AKT/mTOR pathway. To understand the mechanisms underlying 13 xenograftability and associated decreased DSS, we conducted genome-wide gene expression 14 analysis. Our unsupervised cluster analysis showed that the patient tumors (marked with +) 15 cluster alongside their xenografts and xenograft-derived cultured cells (Figure 2A ). The analysis 16 also showed that patient tumors and their xenograft derivatives were closely associated to other 17 high grade patient LPS tumors (red bars) in our database, suggesting that mining the unique 18 gene expression signature within this cluster may help identify the molecular mechanisms 19
underlying the aggressive behavior of this subset of LPS. An example of this analysis is shown 20
in Figure 2B , corresponding to chromosome 12q13.3-23.1, which includes the commonly 21 detected MDM2-CDK4 amplicon ( Figure S2A ). We found that the patient tumors, xenografts, 22
and xenograft-derived cultured cells maintain their own cluster and carry a unique gene 23 expression signature ( Figure 2B highlighted in yellow box). Further global supervised 24 transcriptome analyses identified approximately 1000 genes whose expressions are significantly 25 altered between the passaged tumors and tumors that could be engrafted but not passaged (n=3 each group, p<0.05, two-tail t-test, fold-change >1.5). Importantly, several cell proliferation 1 and invasion related pathways were significantly upregulated in those passaged xenograft 2 samples (Table S1) . 3
We focused on the alteration of the mTOR pathway and hypothesized that PTEN, a 4 tumor suppressor upstream of mTOR, would be responsible for the deregulated mTOR 5 pathway. Although CGH analysis of the patient tumors from which the xenografts were derived 6 showed no genetic alterations at the PTEN locus, 10 expression analysis showed significantly 7
decreased PTEN levels in DD LPS (n=16) when compared to benign lipoma samples (n=10) 8
( Figure 3A; p<0.001, one-way ANOVA). The patient samples and their xenografts also showed 9 low PTEN protein levels, except stroma and blood vessels which have higher PTEN intensity 10 (as indicated by arrows in Figure 3C for representative images of lipoma and LPSX3, Figure  11 S3A for LPSX1 and 2). Furthermore, patient tumors and their derived xenografts had the lowest 12 PTEN expression levels of all DD LPS ( Figure 3A and 3C) , supporting the notion that decreased 13 PTEN expression, most likely due to epigenetic mechanisms, may upregulate the 14 PI3K/AKT/mTOR pathway. Using the expression levels of the benign tumors as a baseline 15 (below 95% confidence interval from the mean expression of benign samples, shown as dotted 16 line in Figure 3A ), we stratified the DD LPS into two groups based on PTEN expression levels 17 ( Figure S3B ). Importantly, low PTEN expression correlated with poor DSS ( Figure 3B ; n=19, 18 p=0.0148, Mantel-Cox test), which suggests that the PTEN controlled PI3K/AKT/mTOR 19 pathway is a potential prognostic signature and therapeutic target for DD LPS. 20
LPS xenografts with low PTEN expression are sensitive to anti-mTOR and multi-kinase 21
inhibitor treatment. To test whether DD LPS with down-regulated PTEN expression and 22 upregulated mTOR pathway activity would be sensitive to targeted inhibition of the 23 PI3K/AKT/mTOR pathway, we treated our xenograft models with rapamycin, a specific inhibitor 24 of mTOR. Although rapamycin has been used clinically for soft tissue sarcoma, it has not been 25 formally evaluated in LPS patients. Recent studies demonstrated that inhibition of mTOR 26 kinase or the PI3K/AKT pathway may cause feedback-dependent activation of upstream AKT 1 and receptor tyrosine kinase signaling, 22-24 leading to therapeutic resistance. We therefore 2 included the multi-targeted tyrosine kinase inhibitor sorafenib in our study design. Sorafenib as 3 single agent has been used in Phase 2 trials for advanced soft tissue sarcomas including LPS, 4 but failed to show significant clinical efficacy. 25 We reasoned that combining sorafenib with 5 rapamycin may block the rapamycin-induced feedback activation of upstream kinases thus 6 leading to sustainable therapeutic effect. 7
Three LPS xenografts (LPSX1, LPSX2, LPSX3) were treated daily with no drug 8 (vehicle), rapamycin only, sorafenib only, or a combination of rapamycin and sorafenib, and 9 tumor growth was monitored over the course of 3-7 weeks or until tumors reached 1.5 cm in 10 diameter. LPSX1 treated with rapamycin or combination therapy showed significantly reduced 11 tumor growth, as measured by tumor volume, when compared to either the vehicle or sorafenib 12 treated groups ( Figure 4A , left panel; Figure S4 ). However, LPSX2 and LPSX3 showed no 13 reduction in tumor size, regardless of treatment ( Figure 4A ; Figure S4 ). 14 There are significant limitations of the current standard size-based RECIST criteria for 15 monitoring response to therapy in soft tissue sarcomas, as tumors may undergo necrosis or 16 differentiation without significant changes in tumor size. We therefore resected all xenograft 17 tumors and examined the effects of various treatments at the histopathologic level. In contrast 18 to the size measurements, all three xenograft models responded to rapamycin and combination 19 treatment with significant necrosis and reduced cellularity, which could be clearly identified in 20 H&E stained sections ( Figure 4B , upper panels for representative images of LPSX3; Figure S5  21 for representative images of LPSX1 and 2). While the vehicle and sorafenib treated tumors 22 retained high cellular density, rapamycin treated tumors were more differentiated with lower 23 cellular density. In support of our hypothesis, combination treatment enhanced the effects of 24 rapamycin with more necrotic areas and further reduced cellularity ( Figure 4B , lower panels; 25 Figure S5 ). In addition to evaluating histopathologic changes, we assessed the intended 26 pathway targets of the drugs using immunohistochemistry. Phospho-S6 was chosen as a 1 surrogate marker of mTOR activity and phospho-ERK was chosen as a downstream surrogate 2 marker of sorafenib treatment. As expected, the levels of phospho-S6 decreased in response to 3 rapamycin and combination treatment. Phospho-ERK levels were relatively equal across 4 treatment groups, with positive staining present in both the nucleus and the cytoplasm ( Figure 5 , 5
representative images of LPSX3, quantification in Table 2 ). Although ERK is known to 6 translocate to the nucleus when phosphorylated, this activated form of the protein has been 7 observed in the cytoplasm in human cancer samples such as melanoma. 26 These 8
histopathologic changes suggest that although the tumor size did not differ among treatment 9 groups of LPSX2 and LPSX3, the tumors responded to rapamycin and combination treatments 10 similarly to LPSX1. 11
Xenograftable DD LPS are more progenitor-like and combination treatment induces 12 differentiation resulting in decreased progenitor expression signature and increased lipid 13
content. Accumulated evidence suggests that different subtypes of LPS may represent 14 developmental blockages of adipocyte differentiation from mesenchymal stem cells. 2 Therefore, 15 inducing differentiation could be a potential therapeutic strategy for LPS. 27,28 One of the 16 morphologic changes we observed after rapamycin and combination treatment was the 17 presence of cells that more closely resembled adipocytes, suggesting potential differentiation. 18
We therefore wanted to determine first if the patient tumors that generated serially-passaged 19
xenografts are more progenitor-like and second whether the combination treatment can alleviate 20 the differentiation blockage. 21
To compare the levels of differentiation of the patient samples, we first used the Rank-22
Rank Hypergeometric Overlap algorithm to compare the overlap of differentially expressed 23 genes in passaged (P) versus non-passaged (NP) patient tumors (Y axis) with those 24 differentially expressed genes of pre-and post-differentiated adipocytes (0 days versus 3 days 25 post-differentiation; data generated by Sohle et al) 14 (X axis). The heat map generated from 26 these comparisons ( Figure 6A , left) showed greatest similarity in the gene expression profile 1 between the passaged tumors and undifferentiated pre-adipocytes, while the non-passaged 2 tumors showed highest similarity to pre-adipocytes day 3 post-differentiation. We then 3 performed the same analysis comparing the gene expression from vehicle (V) and combination 4 (C) treated samples with pre-adipocytes 0 days versus 3 days post-differentiation 14 and found 5 that the combination treatment induced these DD LPSs to initiate the differentiation process 6 ( Figure 6A, right) . 7
To further confirm the differentiation phenotype, we analyzed the fat content of the 8 tumors. We first looked for the presence of lipid droplets by staining with oil red O and found 9
that rapamycin significantly increased both the number and the size of lipid droplets, especially 10 near necrotic areas ( Figure 6B , upper right). Combination treated tumors had a similar extent of 11 oil red O positive cells but with massive necrosis (Figure 6B , lower right and data not shown). 12
Oil red O staining also showed significant regional variations (data not shown). To provide more 13 quantitative measurement, we extracted triglycerides from vehicle and treated tumor samples. 14 Although the response to the individual drugs varied, there was a consistent increase in the 15 triglyceride levels in tumors treated with combination therapy ( Figure 6C ). These results 16 suggest that the passaged tumors are less differentiated and more stem/progenitor-like, at least 17 in part caused by upregulated PI3K pathway. Rapamycin and sorafenib combination treatment 18 not only causes massive tumor necrosis but also leads to adipogenic differentiation of DD LPS 19 tumors that have reduced PTEN levels or hyperactive PI3K/AKT/mTOR pathway. 20
Discussion 21
The xenograft system demonstrated in this study successfully recapitulates the human 22 disease and creates a flexible and useful model for studying the molecular mechanisms 23
underlying LPS. This model also provides a foundation upon which new targets can be 24 developed and novel therapeutics tested. The xenograft model system developed in our study has the potential for prognostic and 1 therapeutic values. However, due to our limited sample size, more samples would need to be 2 tested in order to draw this conclusion. Out of the many clinical variables we tested, including 3 age, sex, location of the tumor, prior treatment history, etc., only size of tumor and presence of 4 multifocal disease correlated with graftability. Moreover, the capability of the tumor to engraft 5 and survive serial passaging directly correlates with poor DSS, a result similar to a recent study 6 of a renal cell carcinoma xenograft model. 29 Thus, the ability for a patient's tumor to engraft 7 may help identify those patients who will benefit from more aggressive treatment regimens. 8
Additionally, since the median interval to disease recurrence is approximately 16 months for 9 patients with high grade LPS, 30 xenografts generated from patient biopsies or resected tumors 10 at the time of initial presentation can be molecularly profiled and interrogated with targeted 11 therapies. This would allow physicians to define appropriate treatment paradigms and institute 12 personalized therapies that could be used to prevent or treat disease recurrence. 13
Our gene expression analysis identified alterations unique to the patient tumors that 14 could be xenografted and serially passaged and suggests that these tumors are more 15 progenitor-like than the non-passaged xenografts. One of the malignant signatures identified 16 through our study is upregulated mTOR pathway activation and lower PTEN gene and protein 17 expression, suggesting that these tumors may have increased sensitivity to the mTOR inhibitor 18 rapamycin. Because rapamycin treatment alone often results in therapeutic resistance, we also 19 included the multi-kinase inhibitor sorafenib. Histologic evaluation of the tumors revealed a 20 noticeable response in all three xenografts to the combination therapy with increased necrosis, 21 decreased cell density, and changes in cell morphology. Further analysis of lipid content and 22 gene expression revealed that the tumors treated with a combination of rapamycin and 23 sorafenib became more differentiated. 24
Xenograft models of renal cell carcinoma generated from patient samples have been 25
shown to reflect clinical response to targeted therapy, 29 demonstrating the use of these models for pre-clinical evaluation of new therapies. The results presented here show that rapamycin 1 and sorafenib combination has potential as a differentiation therapy for those PTEN low or 2 PI3K/AKT/mTOR pathway activated DD LPSs. New mTOR inhibitors that have a greater ability 3 to inhibit mTORC1 activity 31 or dual inhibitors of mTOR and PI3K, able to prevent the AKT 4 feedback loop, 32 may further improve the efficacy of such combination therapies. Another 5 option is to include PPAR ligands as part of treatment. A study on a myxoid liposarcoma 6 mouse model found that addition of PPAR agonists enhanced tumor differentiation achieved by 7 treating with trabectedin. 28 Our study therefore identifies a malignant signature for stratification 8 of patients who may be responsive to differentiation therapy and offer a promising avenue to 9 explore for future targeted and differentiation therapy of DD LPS. 10
Acknowledgements 11
We would like to thank the patients and their families for participating in our research Data are represented as density/intensity of tumor cells staining positively. Density is 2 measured by the following scale: <1: negative; 1: 1-25% tumor cells staining; 2: 26-74% tumor 3 cells staining; 3: >75% tumor cells staining. Intensity is measured as follows: 1+: weak; 2+: 4 moderate; 3+: strong. 5 
Figure Legends

